Chemicals and intermediates used in pharmaceutical manufacturing and drug development.
chemXplore tracks 135 projects in pharma, of which 36 are active.
19 new construction, 16 expansion, and 1 revamp / retrofit.
3 of the active projects carry no start-up date yet.
Owners and developers: Evonik Industries AG (4), Lilly (3), Merck (3), Novo Nordisk (3), Eli Lilly and Company (2), Genentech, Inc. (2)
Investors: Eli Lilly and Company (2), European Investment Bank (2), Evonik Industries AG (2), Takeda (2), AGC Group (1), Clariant AG (1)
Contractors, licensors, and offtakers are recorded on 13 of these 36 projects For subscribers
Targeting: Orforglipron (5), Retatrutide (2), Coagulation factor IX (1), Fumed Silica (1), Glucagon-like peptide-1 (1), Isobutene (1)
Wholly owned Korea subsidiary to secure marketing authorizations and build phased in‑house sales for pipeline drugs including sparsentan and NXT007.
Phase III data showed ARR reductions of 51% and 58% vs teriflunomide and a numerical 12% reduction in PPMS progression versus ocrelizumab; CNS‑penetrant, non‑covalent BTK inhibitor.
Brings acquired specialty-pharma units into a single global management to pursue niche immunology, nephrology, transplant and infectious disease markets; targets ¥300bn by FY2030.
Triple agonist produced up to 20.8% weight loss and up to 1.6% A1C reduction at 80 weeks in adults with type 2 diabetes and obesity.
Two‑year Vibrance‑MG data show maintained MG‑ADL and QMG improvements and steroid reductions in adolescents; HCP survey links fluctuating control to switches to IMAAVY.
Feasibility study to combine Fol‑Dab8 (folate‑conjugated cationic peptide) with naturally occurring microRNA for oligonucleotide therapeutics; undisclosed equity investment made.
Phase‑1 ready oral GLP‑1/GIP dual agonist with up to $2.6bn deal value including $300m upfront; development and commercial rights exclude Greater China.
Exclusive global distribution of GMP‑grade biopharma vitamins for cell culture media; eight B‑vitamin products, multi‑pack sizes and CPHI Milano debut.
Exclusive deal grants development, manufacturing and commercialisation rights for a RAF‑MEK molecular glue; Chugai to receive upfront, royalties and a share of sublicense income.
Real-world claims analysis found escalating from semaglutide 1 mg to 2 mg tied to a 6% lower risk of major adverse cardiovascular events than switching to tirzepatide.
By country, the most active first. active / all projects
The 8 with the most active projects, of 26 countries.
